Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Lectura recomendada por el  Dr. Leandro Recagni. 

Conferencia 2026: «Tratamientos no invasivos del cáncer de próstata a través de la radioterapia»

• Autores:Gerhardt Attard; Laura Murphy; Noel W. Clarke; William Cross; Robert J. Jones; Christopher C. Parker; Silke Gillessen; Adrian Cook; Chris Brawley; Claire L. Amos; Nafisah Atako; Cheryl Pugh; et al.

• Fuente:The Lancet. 2022;399:447–460.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Descargar